Recipham to Expand Lyophilization Capacity in Germany
Recipharm has invested EUR 32 million ($43 million) in its Wasserburg, Germany site to expand lyophilization capacity.
Recipharm will invest EUR 32 million ($43 million) in its Wasserburg, Germany site located near Munich to create a new building that will house a fourth production area adding to the three already in operation. This development will increase the company’s lyophilization capacity and automatic loading and unloading technology. The building will also have the flexibility to accommodate further production lines. The number of employees will be increased from the current 282 to 320, and the new area is expected to be operational in 2016.
Source: Recipharm
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
